Dapagliflozin [461432-26-8]
Référence T2389-100mg
Conditionnement : 100mg
Marque : TargetMol
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Dapagliflozin
(Synonyms: BMS-512148) Copy Product Info
Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.
Cas No. 461432-26-8
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.93%
Color:White
COA HNMR LCMS
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. |
| Targets & IC50 | SGLT2 (human):1.1 nM (EC50), Caco-2 cells viability:167.8 μM (48h), A549 cells viability:287.5 μM (48h), MCF-7 cells viability:243.4 μM (48h), Du-145 cells viability:290.1 μM (48h), PANC1 cells viability:435.7 μM (48h) |
| In vitro | METHODS: The human proximal tubule epithelial cell line HK2 was treated with Dapagliflozin (1-10 µM) under normoxic and hypoxic conditions for 24 h. Cell viability was assayed using Trypan blue staining. RESULTS: Dapagliflozin pretreatment had no effect on cell survival of normoxic HK2 cells. Hypoxia significantly reduced the cell viability of HK2 cells compared to control cells, and Dapagliflozin pretreatment of hypoxic HK2 cells significantly increased cell viability in a dose-dependent manner. [1] METHODS: The human proximal tubule epithelial cell line HK2 was treated with Dapagliflozin (0.1 µM) and H2O2 (200 µM) for 24 h. Apoptosis was detected using Hoechst 33342 and PI. RESULTS: Dapagliflozin significantly reduced the percentage of apoptotic cell death induced by H2O2.Dapagliflozin had a protective effect against H2O2-induced cell death. [2] |
| In vivo | METHODS: To investigate the effects on diabetic atherosclerosis, Dapagliflozin (1 mg/kg) was administered by gavage to diabetic ApoE-/- mice with high-fat diet-induced atherosclerosis once daily for 12 weeks. RESULTS: Dapagliflozin may have therapeutic potential for high-fat diet-induced diabetic atherosclerosis, and these benefits may depend on the inhibition of IL-1β secretion by macrophages via the ROS-NLRP3-caspase-1 pathway. [3] |
| Synonyms | BMS-512148 |
| Cell Research | To perform the cell survival assay, cells are collected after 24 h incubation with vehicle or dapagliflozin pretreatment in 30-min ischemia and surviving cells are counted with Trypan blue staining. The percentage survival is determined by quantization of the relative viable number of treated cells divided by the viable number of untreated cells. |
| Molecular Weight | 408.87 |
| Formula | C21H25ClO6 |
| Cas No. | 461432-26-8 |
| Smiles | O[C@H]1[C@@H](O[C@H](CO)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=C(OCC)C=C3)=C(Cl)C=C2 |
| Relative Density. | 1.349 |
| Storage | Store under nitrogen,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 14 mg/mL (34.24 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 247.5 mg/mL (605.33 mM), Sonication is recommended.  | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4.5 mg/mL (11.01 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||